PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pharvaris N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Apr 2, 2026
$29.77+2.03 (+7.32%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | -42.7% | – | |
| Interest coverage | – | -281.9× | – | |
| Diluted shares | – | 5M | 59M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pharvaris generated €462.02M from operations and spent €1.05M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
€462.02M
Used
€1.05M
Capital expenditure€1.05M100%Dividends€00%Share buybacks€00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 2 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-€137.07M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-€137.07M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → –
- No dilutionShare count did not rise54M → 59M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –